Clinical Trial

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2028-04 2026-08-14
minor Completion pushed: 2028-01 -> 2028-12 2026-08-14
Trial Details
NCT Number NCT05733715
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Merck Sharp & Dohme LLC
Conditions Renal Cell Carcinoma
Enrollment 30 participants
Start Date 2023-05-03
Primary Completion 2028-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-13